The pattern of inflammatory/anti-inflammatory cytokines and chemokines in type 1 diabetic patients over time

References

• Daneman D. Type 1 diabetes. Lancet. 2006;367:847–58.
   PubMed Web of Science ®Google Scholar
• Roep BO. The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure. Diabetologia. 2003;46:305–21.
   PubMed Web of Science ®Google Scholar
• Chase HP, MacKenzie TA, Burdick J, Fiallo-Scharer R, Walravens P, Klingensmith G, . Redefining the clinical remission period in children with type 1 diabetes. Pediatr Diabetes. 2004;5:16–19.
   PubMed Web of Science ®Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977–86.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.
   PubMed Web of Science ®Google Scholar
• Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM, . Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia. 1999;42:351–7.
   PubMed Web of Science ®Google Scholar
• Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes. 2006;55:774–9.
   PubMed Web of Science ®Google Scholar
• Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—the EURODIAB Prospective Complications Study. Diabetologia. 2005;48: 370–8.
   PubMed Web of Science ®Google Scholar
• Devaraj S, Cheung AT, Jialal I, Griffen SC, Nguyen D, Glaser N, . Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes. 2007;56:2790–6.
   PubMed Web of Science ®Google Scholar
• Lin J, Glynn RJ, Rifai N, Manson JE, Ridker PM, Nathan DM, . Inflammation and progressive nephropathy in type 1 diabetes in the diabetes control and complications trial. Diabetes Care. 2008;31:2338–43.
   PubMed Web of Science ®Google Scholar
• Kim EY, Moudgil KD. Regulation of autoimmune inflammation by pro-inflammatory cytokines. Immunol Lett. 2008;120:1–5.
   PubMed Web of Science ®Google Scholar
• Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocr Rev. 2007;28:492–520.
   PubMed Web of Science ®Google Scholar
• Almawi WY, Tamim H, Azar ST. Clinical review 103: T helper type 1 and 2 cytokines mediate the onset and progression of type I (insulin-dependent) diabetes. J Clin Endocrinol Metab. 1999;84:1497–502.
   PubMed Web of Science ®Google Scholar
• Rabinovitch A, Suarez-Pinzon WL. Role of cytokines in the pathogenesis of autoimmune diabetes mellitus. Rev Endocr Metab Disord. 2003;4:291–9.
   PubMed Web of Science ®Google Scholar
• Targher G, Zenari L, Bertolini L, Muggeo M, Zoppini G. Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications. Diabetes Care. 2001;24:956–7.
   PubMed Web of Science ®Google Scholar
• Mohamed-Ali V, Armstrong L, Clarke D, Bolton CH, Pinkney JH. Evidence for the regulation of levels of plasma adhesion molecules by proinflammatory cytokines and their soluble receptors in type 1 diabetes. J Intern Med. 2001;250:415–21.
   PubMed Web of Science ®Google Scholar
• Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, . Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106:2067–72.
   PubMed Web of Science ®Google Scholar
• Gordin D, Forsblom C, Ronnback M, Parkkonen M, Waden J, Hietala K, . Acute hyperglycaemia induces an inflammatory response in young patients with type 1 diabetes. Ann Med. 2008;40:627–33.
   PubMed Web of Science ®Google Scholar
• Haller MJ, Schatz DA. Cytokines and type 1 diabetes complications: casual or causal association? Pediatr Diabetes. 2008;9:1–2.
   PubMed Web of Science ®Google Scholar
• van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67:2–17.
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001;58:4–43.
   PubMed Web of Science ®Google Scholar
• Rizvi M, Pathak D, Freedman JE, Chakrabarti S. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol Med. 2008;14:530–8.
   PubMed Web of Science ®Google Scholar
• Toubi E, Shoenfeld Y. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity. 2004;37:457–64.
   PubMed Web of Science ®Google Scholar
• Lutgens E, Lievens D, Beckers L, Donners M, Daemen M. CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med. 2007;17:118–23.
   PubMed Web of Science ®Google Scholar
• Vosters O, Beuneu C, Nagy N, Movahedi B, Aksoy E, Salmon I, . CD40 expression on human pancreatic duct cells: role in nuclear factor-kappa B activation and production of pro-inflammatory cytokines. Diabetologia. 2004;47:660–8.
   PubMed Web of Science ®Google Scholar
• Barbe-Tuana FM, Klein D, Ichii H, Berman DM, Coffey L, Kenyon NS, . CD40-CD40 ligand interaction activates proinflammatory pathways in pancreatic islets. Diabetes. 2006;55:2437–45.
   PubMed Web of Science ®Google Scholar
• Wagner DH Jr, Vaitaitis G, Sanderson R, Poulin M, Dobbs C, Haskins K. Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes. Proc Natl Acad Sci U S A. 2002;99:3782–7.
   PubMed Web of Science ®Google Scholar
• Chatzigeorgiou A, Lembessis P, Mylona-Karagianni C, Tsouvalas E, Diamanti-Kandarakis E, Kamper EF. CD40 expression and its association with low-grade inflammation in a Greek population of type 1 diabetic juveniles: evidence for differences in CD40 mRNA isoforms expressed by peripheral blood mononuclear cells Exp Clin Endocrinol Diabetes. 2010;118:38–46.
   PubMed Web of Science ®Google Scholar
• Jinchuan Y, Zonggui W, Jinming C, Li L, Xiantao K. Upregulation of CD40–CD40 ligand system in patients with diabetes mellitus. Clin Chim Acta. 2004;339:85–90.
   PubMed Web of Science ®Google Scholar
• Chiarelli F, Giannini C, Verrotti A, Mezzetti A, Mohn A. Increased concentrations of soluble CD40 ligand may help to identify type 1 diabetic adolescents and young adults at risk for developing persistent microalbuminuria. Diabetes Metab Res Rev. 2008;24:570–6.
   PubMed Web of Science ®Google Scholar
• Rosa JS, Flores RL, Oliver SR, Pontello AM, Zaldivar FP, Galassetti PR. Sustained IL-1alpha, IL-4, and IL-6 elevations following correction of hyperglycemia in children with type 1 diabetes mellitus. Pediatr Diabetes. 2008;9:9–16.
   PubMed Web of Science ®Google Scholar
• Mylona-Karayanni C, Gourgiotis D, Bossios A, Kamper EF. Oxidative stress and adhesion molecules in children with type 1 diabetes mellitus: a possible link. Pediatr Diabetes. 2006;7:51–9.
   PubMed Web of Science ®Google Scholar
• Khuu HM, Robinson CA, Goolsby K, Hardy RW, Konrad RJ. Evaluation of a fully automated high-performance liquid chromatography assay for hemoglobin A1c. Arch Pathol Lab Med. 1999;123:763–7.
   PubMed Web of Science ®Google Scholar
• Podani J. On the sensitivity of ordination and classification methods to variation in the input order of data. Journal of Vegetation Science. 1997;8:153–6.
   Web of Science ®Google Scholar
• van der Kloot WA, Spanns AMJ, Heiser WJ. Instability of hierarchical cluster analysis due to the input order of the data: The PermuCLUSTER solution. Psychol Methods. 2005;10:468–76.
   PubMed Web of Science ®Google Scholar
• Sokal RR, Rohlf FJ. The comparison of dendrograms by objective methods. Taxon. 1962;11:33–41.
   Google Scholar
• Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol. 2009;5:219–26.
   PubMed Web of Science ®Google Scholar
• Basu S, Larsson A, Vessby J, Vessby B, Berne C. Type 1 diabetes is associated with increased cyclooxygenase- and cytokine-mediated inflammation. Diabetes Care. 2005; 28:1371–5.
   PubMed Web of Science ®Google Scholar
• Dogan Y, Akarsu S, Ustundag B, Yilmaz E, Gurgoze MK. Serum IL-1beta, IL-2, and IL-6 in insulin-dependent diabetic children. Mediators Inflamm. 2006;2006:59206.
   PubMedGoogle Scholar
• Shanmugam N, Reddy MA, Guha M, Natarajan R. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes. 2003;52:1256–64.
   PubMed Web of Science ®Google Scholar
• Foss-Freitas MC, Foss NT, Donadi EA, Foss MC. Effect of the glycemic control on intracellular cytokine production from peripheral blood mononuclear cells of type 1 and type 2 diabetic patients. Diabetes Res Clin Pract. 2008;82:329–34.
   PubMed Web of Science ®Google Scholar
• Alexandraki KI, Piperi C, Ziakas PD, Apostolopoulos NV, Makrilakis K, Syriou V, . Cytokine secretion in long-standing diabetes mellitus type 1 and 2: associations with low-grade systemic inflammation. J Clin Immunol. 2008; 28:314–21.
   PubMed Web of Science ®Google Scholar
• Opal SM, DePalo VA. Anti-inflammatory cytokines. Chest. 2000;117:1162–72.
   PubMed Web of Science ®Google Scholar
• Stechova K, Bohmova K, Vrabelova Z, Sepa A, Stadlerova G, Zacharovova K, . High T-helper-1 cytokines but low T-helper-3 cytokines, inflammatory cytokines and chemokines in children with high risk of developing type 1 diabetes. Diabetes Metab Res Rev. 2007;23:462–71.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Oxenius A. Interleukin 2: from immunostimulation to immunoregulation and back again. EMBO Rep. 2007;8:1142–8.
   PubMed Web of Science ®Google Scholar
• Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell. 1996;85:291–7.
   PubMed Web of Science ®Google Scholar
• Fisman EZ, Adler Y, Tenenbaum A. Biomarkers in cardiovascular diabetology: interleukins and matrixins. Adv Cardiol. 2008;45:44–64.
   PubMed Web of Science ®Google Scholar
• Bradley LM, Asensio VC, Schioetz LK, Harbertson J, Krahl T, Patstone G, . Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes. J Immunol. 1999;162:2511–20.
   PubMed Web of Science ®Google Scholar
• Maxwell PR, Timms PM, Chandran S, Gordon D. Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with type 1 diabetes. Diabet Med. 2001;18:777–80.
   PubMed Web of Science ®Google Scholar
• Xue M, Thompson PJ, Clifton-Bligh R, Fulcher G, Gallery ED, Jackson C. Leukocyte matrix metalloproteinase-9 is elevated and contributes to lymphocyte activation in type I diabetes. Int J Biochem Cell Biol. 2005;37:2406–16.
   PubMed Web of Science ®Google Scholar
• Jacqueminet S, Ben Abdesselam O, Chapman MJ, Nicolay N, Foglietti MJ, Grimaldi A, . Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy. Clin Chim Acta. 2006;367:103–7.
   PubMed Web of Science ®Google Scholar
• Gaudreau S, Guindi C, Menard M, Besin G, Dupuis G, Amrani A. Granulocyte-macrophage colony-stimulating factor prevents diabetes development in NOD mice by inducing tolerogenic dendritic cells that sustain the suppressive function of CD4+CD25+ regulatory T cells. J Immunol. 2007;179:3638–47.
   PubMed Web of Science ®Google Scholar
• Gangi E, Vasu C, Cheatem D, Prabhakar BS. IL-10-producing CD4+CD25+ regulatory T cells play a critical role in granulocyte-macrophage colony-stimulating factor-induced suppression of experimental autoimmune thyroiditis. J Immunol. 2005;174:7006–13.
   PubMed Web of Science ®Google Scholar
• Krakowski M, Abdelmalik R, Mocnik L, Krahl T, Sarvetnick N. Granulocyte macrophage-colony stimulating factor (GM-CSF) recruits immune cells to the pancreas and delays STZ-induced diabetes. J Pathol. 2002;196:103–12.
   PubMed Web of Science ®Google Scholar
• Maurer M, von Stebut E. Macrophage inflammatory protein-1. Int J Biochem Cell Biol. 2004;36:1882–6.
   PubMed Web of Science ®Google Scholar
• Lohmann T, Laue S, Nietzschmann U, Kapellen TM, Lehmann I, Schroeder S, . Reduced expression of Th1-associated chemokine receptors on peripheral blood lymphocytes at diagnosis of type 1 diabetes. Diabetes. 2002;51:2474–80.
   PubMed Web of Science ®Google Scholar
• Pfleger C, Kaas A, Hansen L, Alizadeh B, Hougaard P, Holl R, . Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes. Clin Immunol. 2008;128:57–65.
   PubMed Web of Science ®Google Scholar
• Chatzigeorgiou A, Lyberi M, Chatzilymperis G, Nezos A, Kamper E. CD40/CD40L signaling and its implication in health and disease. Biofactors. 2009;35:474–83.
   PubMed Web of Science ®Google Scholar
• Contin C, Pitard V, Delmas Y, Pelletier N, Defrance T, Moreau JF, . Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients. Immunology. 2003;110:131–40.
   PubMed Web of Science ®Google Scholar
• van Kooten C, Gaillard C, Galizzi JP, Hermann P, Fossiez F, Banchereau J, . B cells regulate expression of CD40 ligand on activated T cells by lowering the mRNA level and through the release of soluble CD40. Eur J Immunol. 1994;24:787–92.
   PubMed Web of Science ®Google Scholar
• Sharma MD, Leite de Moraes M, Zavala F, Pontoux C, Papiernik M. Induction and inhibition of CD40-CD40 ligand interactions: a new strategy underlying host-virus relationships. J Immunol. 1998;161:5357–65.
   PubMed Web of Science ®Google Scholar
• Eshel D, Toporik A, Efrati T, Nakav S, Chen A, Douvdevani A. Characterization of natural human antagonistic soluble CD40 isoforms produced through alternative splicing. Mol Immunol. 2008;46:250–7.
   PubMed Web of Science ®Google Scholar
• Contin C, Pitard V, Itai T, Nagata S, Moreau JF, Dechanet-Merville J. Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme. Implications for CD40 signaling. J Biol Chem. 2003;278: 32801–9.
   PubMed Web of Science ®Google Scholar
• Chase HP, Cooper S, Osberg I, Stene LC, Barriga K, Norris J, . Elevated C-reactive protein levels in the development of type 1 diabetes. Diabetes. 2004;53:2569–73.
   PubMed Web of Science ®Google Scholar
• Ludvigsson J. Immune intervention at diagnosis—should we treat children to preserve beta-cell function? Pediatr Diabetes. 2007;8 Suppl 6:34–9.
   PubMedGoogle Scholar
• von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol. 2007;7:988–94.
   PubMed Web of Science ®Google Scholar
• Cameron MJ, Arreaza GA, Grattan M, Meagher C, Sharif S, Burdick MD, . Differential expression of CC chemokines and the CCR5 receptor in the pancreas is associated with progression to type I diabetes. J Immunol. 2000;165: 1102–10.
   PubMed Web of Science ®Google Scholar
• Chistiakov DA, Voronova NV, Chistiakov PA. The crucial role of IL-2/IL-2RA-mediated immune regulation in the pathogenesis of type 1 diabetes, an evidence coming from genetic and animal model studies. Immunol Lett. 2008; 118:1–5.
   PubMed Web of Science ®Google Scholar
• Eisenstein EM, Williams CB. The T(reg)/Th17 cell balance: a new paradigm for autoimmunity. Pediatr Res. 2009; 65:26R–31R.
   PubMed Web of Science ®Google Scholar
• Boissier MC, Assier E, Biton J, Denys A, Falgarone G, Bessis N. Regulatory T cells (Treg) in rheumatoid arthritis. Joint Bone Spine. 2009;76:10–14.
   PubMed Web of Science ®Google Scholar